Myriad Genetics (Nasdaq:MYGN) hit a new 52-week high Thursday as it is currently trading at $36.39, above its previous 52-week high of $34.70 with 1.2 million shares traded as of 10:31 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Thursday as it is currently trading at $36.39, above its previous 52-week high of $34.70 with 1.2 million shares traded as of 10:31 a.m. ET. Average volume has been 1.1 million shares over the past 30 days. Myriad has a market cap of $2.73 billion and is part of the services sector and diversified services industry. Shares are up 25.7% year to date as of the close of trading on Wednesday. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Myriad as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Myriad Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..